Print this page
-
A Prospective Trial of Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for the Treatment of Metastatic Lung Cancer: SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
Protocol: 031907Principal Investigator:
- David D'Ambrosio (Community Medical Center)
Applicable Disease Sites: Lung -
Molecular Monitoring with Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma
Protocol: 011908Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
NCI/CTEP #10266: A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced Non Small Cell Lung Cancer Previously Treated with Immunotherapy
Protocol: 031923Principal Investigator:
- Jyoti Malhotra MD, MPH (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A051701: Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas.
Protocol: 012001Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab
Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Protocol: 011813Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Kristen Spencer DO, MPH (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Any Site
